Abstract
SARS-CoV-2 vaccination has proven effective in inducing an immune response in healthy individuals and is progressively allowing to overcome the pandemic. Recent evidence has shown that response to vaccination in some vulnerable patients may be diminished, and it has been proposed a booster dose. We tested the kinetic of development of serum antibodies to the SARS-CoV-2 Spike protein, their neutralizing capacity, the CD4 and CD8 IFN-γ T cell response in 328 subjects, including 131 immunocompromised individuals (cancer, rheumatologic, and hemodialysis patients), 160 healthcare workers (HCW) and 37 subjects older than 75 yo, after vaccination with two or three doses of mRNA vaccines. We stratified the patients according to the type of treatment. We found that immunocompromised patients, depending on the type of treatment, poorly respond to SARS-CoV-2 mRNA vaccines. However, an additional booster dose of vaccine induced a good immune response in almost all of the patients except those receiving anti-CD20 antibody. Similarly to HCW, previously infected and vaccinated immunocompromised individuals demonstrate a stronger SARS-CoV-2 specific immune response than those who are vaccinated without prior infection.
Summary blurb Immunocompromised patients poorly respond to two doses of SARS-CoV-2 mRNA vaccines. However, an additional booster dose elicits a strong humoral and cellular immune response in these subjects.
Competing Interest Statement
F.B., M.C., N.C., and B.O. are employees of DiaSorin S.p.A., the manufacturer of the LIAISON SARSCoV-2 TrimericS IgG test. Employees of DiaSorin participated in the study design, data collection and interpretation and in the preparation of the manuscript. M.R. participated to advisory boards and received support from Diasorin S.p.A. Other authors have declared that no conflict of interest exists.
Funding Statement
This work was supported by DiaSorin S.p.A. and Ricerca Corrente (Ministero della Salute, to M.R and A.M.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We tested the IgG antibody response, the CD4 and CD8 T cell activation and the neutralizing antibody response to SARS-CoV-2 spike protein developed after mRNA SARS-CoV-2 vaccination (Spikevax or Comirnaty) as a part of two observational studies (CLI-PR-2102 and CLI-PR-2108) approved by the Ethical Committee of Istituto Clinico Humanitas, in compliance with the Declaration of Helsinki principles. The studies were conducted at Istituto Clinico Humanitas.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We changed the title and we replaced "fragile" with "immunocompromised" in the manuscript. Methods section updated to clarify "Detection of SARS-CoV-2 specific cell-mediated immunity". Discussion section updated to clarify the limitations of the study. Supplemental files updated (we added 3 supplementary figures).
Data Availability
All data produced in the present study are available upon reasonable request to the authors